$SLS News

Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout

Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal

SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?

SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses

SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Sellas Life Sciences: Behind The Big Surge

Sellas Life Sciences Group Files Shelf Prospectus For Offering Of Securities; No Terms Disclosed

SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate

SELLAS Life Sciences Group To Reveal Preclinical Data On SLS009 In A Poster Session At The American Association For Cancer Research Taking Place April 17-22 At San Diego Convention Center In San Diego, CA

SELLAS Life Sciences Announces First Patient Enrolled In Randomized Phase 2 Trial Evaluating SLS009, CDK9 Inhibitor In Newly Diagnosed, First-Line AML Patients

Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst

What's Going With SELLAS Life Sciences Stock On Wednesday?

Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal

A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Enters Into Agreement With IMPACT-AML To Launch European Clinical Study Of SLS009

SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed?

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)